'Novoseven rt' presentation slideshows

Novoseven RT Industry (Hemophilia A and B) in Depth Analysis

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. Novo Nordisk

223 views • 6 slides